136 related articles for article (PubMed ID: 10521457)
1. Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP.
Morris SK; Lindsley JE
J Biol Chem; 1999 Oct; 274(43):30690-6. PubMed ID: 10521457
[TBL] [Abstract][Full Text] [Related]
2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
3. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193.
Morris SK; Baird CL; Lindsley JE
J Biol Chem; 2000 Jan; 275(4):2613-8. PubMed ID: 10644721
[TBL] [Abstract][Full Text] [Related]
4. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP.
Harkins TT; Lewis TJ; Lindsley JE
Biochemistry; 1998 May; 37(20):7299-312. PubMed ID: 9585544
[TBL] [Abstract][Full Text] [Related]
5. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
6. The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) release.
Baird CL; Gordon MS; Andrenyak DM; Marecek JF; Lindsley JE
J Biol Chem; 2001 Jul; 276(30):27893-8. PubMed ID: 11353771
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II drives DNA transport by hydrolyzing one ATP.
Baird CL; Harkins TT; Morris SK; Lindsley JE
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13685-90. PubMed ID: 10570133
[TBL] [Abstract][Full Text] [Related]
8. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II.
Lindsley JE; Wang JC
J Biol Chem; 1993 Apr; 268(11):8096-104. PubMed ID: 8385137
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
10. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis.
Harkins TT; Lindsley JE
Biochemistry; 1998 May; 37(20):7292-8. PubMed ID: 9585543
[TBL] [Abstract][Full Text] [Related]
11. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA.
Leroy D; Kajava AV; Frei C; Gasser SM
Biochemistry; 2001 Feb; 40(6):1624-34. PubMed ID: 11327821
[TBL] [Abstract][Full Text] [Related]
12. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
15. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Robinson MJ; Osheroff N
Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
[TBL] [Abstract][Full Text] [Related]
16. Communication between the ATPase and cleavage/religation domains of human topoisomerase IIalpha.
Bjergbaek L; Kingma P; Nielsen IS; Wang Y; Westergaard O; Osheroff N; Andersen AH
J Biol Chem; 2000 Apr; 275(17):13041-8. PubMed ID: 10777608
[TBL] [Abstract][Full Text] [Related]
17. A two-site kinetic mechanism for ATP binding and hydrolysis by E. coli Rep helicase dimer bound to a single-stranded oligodeoxynucleotide.
Hsieh J; Moore KJ; Lohman TM
J Mol Biol; 1999 Apr; 288(2):255-74. PubMed ID: 10329141
[TBL] [Abstract][Full Text] [Related]
18. Catalysis of ATP hydrolysis by two NH(2)-terminal fragments of yeast DNA topoisomerase II.
Olland S; Wang JC
J Biol Chem; 1999 Jul; 274(31):21688-94. PubMed ID: 10419479
[TBL] [Abstract][Full Text] [Related]
19. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
20. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization.
Hu T; Sage H; Hsieh TS
J Biol Chem; 2002 Feb; 277(8):5944-51. PubMed ID: 11850431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
